0000899243-19-004863.txt : 20190226
0000899243-19-004863.hdr.sgml : 20190226
20190226160614
ACCESSION NUMBER: 0000899243-19-004863
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190222
FILED AS OF DATE: 20190226
DATE AS OF CHANGE: 20190226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BJERKHOLT ERIC
CENTRAL INDEX KEY: 0001197350
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 19633404
MAIL ADDRESS:
STREET 1: 132 PURDURE AVENUE
CITY: KENGSINGTON
STATE: CA
ZIP: 94708
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-22
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001197350
BJERKHOLT ERIC
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
0
1
0
0
Chief Financial Officer
Common Stock, $0.0001 par value
2019-02-22
4
A
0
13125
0.00
A
32857
D
Stock Option (right to buy)
23.72
2019-02-22
4
A
0
78750
0.00
A
2029-02-22
Common Stock
78750
78750
D
These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 9,375 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 247 shares acquired on November 15, 2018 pursuant to Issuer's employee stock purchase plan.
The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Douglas T. Sheehy, as Attorney in Fact for Eric Bjerkholt
2019-02-26